Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02291432 · ClinicalTrials.gov registry record · Phase 1
Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery
A Phase 1 study, sponsored by Cook MyoSite.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02291432 is a Phase 1 study that has completed, run by Cook MyoSite. The registered enrollment target is 25 participants.
The verdict
NCT02291432, a Phase 1 study, has completed, sponsored by Cook MyoSite.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
To study the safety and potential efficacy of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) for the treatment of male stress urinary incontinence (SUI) for patients that have undergone prior prostate surgery.
Interventions
- BIOLOGICAL autologous muscle-derived cells (AMDC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-02-19 |
| Est. Completion | 2019-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02291432
The ClinicalTrials.gov registry entry for NCT02291432 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cook MyoSite, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which autologous muscle-derived cells (AMDC) is the first listed.
NCT02291432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02291432 about?
NCT02291432 is a clinical study titled "Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery". To study the safety and potential efficacy of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) for the treatment of male stress urinary incontinence (SUI) for patients that have undergone prior prostate surgery.
What is the current status of trial NCT02291432?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2015-02-19. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT02291432?
The interventions under investigation include: autologous muscle-derived cells (AMDC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02291432?
This trial is sponsored by Cook MyoSite, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.